Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Displaced Proximal Humeral Fractures: Delta Prothesis or Philos Plate? (DELPHI)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Oslo University Hospital
Sponsor:
Collaborators:
Sykehuset Telemark
Sykehuset Asker og Baerum
Sykehuset Ostfold
Helse Førde
Sykehuset i Vestfold HF
Diakonhjemmet Hospital
Information provided by (Responsible Party):
Tore Fjalestad, Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT01737060
First received: November 20, 2012
Last updated: October 3, 2014
Last verified: October 2014
  Purpose

To investigate the assumption that reversed shoulder prosthetic replacement will give a better functional outcome compared to open reduction and internal fixation with an angular stable plate in displaced proximal humeral fractures.


Condition Intervention
Proximal Humeral Fractures, AO Group B2 and C2
Device: Reverse total shoulder arthroplasty

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Clinical Investigation for Fractures of the Proximal Humerus in Elderly Patients. A Randomized Study of Two Surgical Treatments: Reverse Total Shoulder Arthroplasty Versus Angular Stable Device Philos

Resource links provided by NLM:


Further study details as provided by Oslo University Hospital:

Primary Outcome Measures:
  • Constant Shoulder Score [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
    Follow-up will be at 3-6-12 months and 2-5 years.


Secondary Outcome Measures:
  • Oxford Shoulder score [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Follow-up will be at 3-6-12 months and 2-5 years.


Other Outcome Measures:
  • 15D Quality of Life score [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Follow-up will be at 3-6-12 months and 2-5 years.

  • Health Economics [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Follow-up will be at 3-6-12 months and 2-5 years.


Estimated Enrollment: 120
Study Start Date: January 2013
Estimated Study Completion Date: June 2021
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Angular stable plate Philos
Open Reduction and Osteofixation with Philos plate and TiCron cerclages
Device: Reverse total shoulder arthroplasty
Other Name: Delta Xtend shoulder proshesis
Experimental: Reverse Total Shoulder Artroplasty
Intervention group
Device: Reverse total shoulder arthroplasty
Other Name: Delta Xtend shoulder proshesis

Detailed Description:

RTSA equals Delta Xtend reversed total shoulder prosthesis. Angular stable plate means Proximal humerus plate (Philos)

  Eligibility

Ages Eligible for Study:   65 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patient admitted in hospital with a displaced three- or four part proximal humerus fracture of OTA / AO group 11-B2 or 11-C2 (displaced fracture of extra-articular or articular, bifocal type). The subgroups -.1, -.2 and -.3 will be included for both B2 and C2 groups, provided severe displacement: This is defined as a mal-position of at least 45º of angular deviation in valgus or 30º in varus in true frontal projection, regardless of whether the fracture is impacted or not, or less than 50% contact between humeral head and the metaphyseal part of the shaft. The greater or lesser tubercle displaced at least 10 mm.

Exclusion Criteria:

Patient younger than 65 years or older than 85 years, previous history of injury or illness of the injured shoulder, injuries of other parts of the humerus or the contra-lateral upper extremity, alcohol- or drug abuse, dementia, neurological diseases, or severe cardiovascular or lung diseases that would contraindicate surgery. Patients have to understand the Norwegian language and be compliant to rehabilitation and follow-ups.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01737060

Contacts
Contact: Tore Fjalestad, MD, PhD. 0047 22118080 tofjal@ous-hf.no
Contact: Jan Erik Madsen, MD, Professor 0047 22118080 j.e.madsen@klinmed.uio.no

Locations
Norway
Oslo University Hospital Recruiting
Oslo, Norway
Contact: Tore Fjalestad, MD, PhD    0047 22118080    tofjal@ous-hf.no   
Principal Investigator: Tore Fjalestad, MD, PhD         
Sponsors and Collaborators
Oslo University Hospital
Sykehuset Telemark
Sykehuset Asker og Baerum
Sykehuset Ostfold
Helse Førde
Sykehuset i Vestfold HF
Diakonhjemmet Hospital
  More Information

Additional Information:
Publications:
Responsible Party: Tore Fjalestad, MD PhD Consultant, Oslo University Hospital
ClinicalTrials.gov Identifier: NCT01737060     History of Changes
Other Study ID Numbers: RTSA s422
Study First Received: November 20, 2012
Last Updated: October 3, 2014
Health Authority: National Committee for Medical and Health Research Ethics Norway:

Keywords provided by Oslo University Hospital:
Reversed prosthesis, Philos, Severe displaced

Additional relevant MeSH terms:
Fractures, Bone
Humeral Fractures
Shoulder Fractures
Arm Injuries
Wounds and Injuries

ClinicalTrials.gov processed this record on November 27, 2014